Request Demo
Last update 20 Mar 2025
Recombinant humanized monoclonal antibody MIL93(Beijing Mabworks Biotech Co., Ltd.)
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms |
Target |
Action inhibitors |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Recombinant humanized monoclonal antibody MIL93(Beijing Mabworks Biotech Co., Ltd.)CTR20202436
评价重组人源化单克隆抗体MIL93 注射液治疗局部晚期或转移性实体瘤的耐受性、安全性、药代动力学和初步疗效的I/Ⅱ期临床研究
[Translation] A phase I/II clinical study to evaluate the tolerability, safety, pharmacokinetics and preliminary efficacy of recombinant humanized monoclonal antibody MIL93 injection in the treatment of locally advanced or metastatic solid tumors
NCT04671875
A Phase I Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of MIL93 in Advanced or Metastatic Solid Tumors.
100 Clinical Results associated with Recombinant humanized monoclonal antibody MIL93(Beijing Mabworks Biotech Co., Ltd.)
Login to view more data
100 Translational Medicine associated with Recombinant humanized monoclonal antibody MIL93(Beijing Mabworks Biotech Co., Ltd.)
Login to view more data
100 Patents (Medical) associated with Recombinant humanized monoclonal antibody MIL93(Beijing Mabworks Biotech Co., Ltd.)
Login to view more data
100 Deals associated with Recombinant humanized monoclonal antibody MIL93(Beijing Mabworks Biotech Co., Ltd.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Biliary Tract Neoplasms | Phase 2 | China | 21 Apr 2021 | |
| CLDN18.2 positive Gastrooesophageal junction cancer | Phase 2 | China | - | |
| CLDN18.2 positive Pancreatic Cancer | Phase 2 | China | - | |
| CLDN18.2 positive Stomach Cancer | Phase 2 | China | - | |
| Metastatic Solid Tumor | Phase 1 | China | 21 Apr 2021 | |
| CLDN18.2 Positive Gastrointestinal Neoplasms | IND Approval | China | 29 Dec 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 30 | (xubyfcdmfc) = drouwnzftv dfegauoahp (xapribyuum ) View more | Positive | 24 Jan 2023 | |||
Phase 1 | 13 | (bwqvtopfky) = znlnoydudp mgreyyseoo (dndyqyzqek ) View more | Positive | 02 Jun 2022 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free